Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccines for latent viruses.

F Pass1

  • 1Molecular Genetics, Inc., Minnetonka, MN.

Journal of the American Academy of Dermatology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Modern vaccine development utilizes recombinant DNA technology to create subunit vaccines. These advanced viral vaccines are non-infectious and non-oncogenic, offering safer immunization strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delivery of insulin by jet injection: recent observations.

Diabetes technology & therapeutics·2001
Same author

Human papillomavirus heterogeneity in 36 renal transplant recipients.

Archives of dermatology·1987
Same author

Applications of biotechnology to human-papillomavirus-induced diseases.

Clinics in dermatology·1985
Same author

Sodium lauryl sulfate irritant patch tests. II. Variations of test responses among subjects and comparison to variations of allergic responses elicited by Toxicodendron extract.

Journal of the American Academy of Dermatology·1984
Same author

Toxicodendron antigen patch test. Degrees of inflammation observed after various time intervals.

Archives of dermatology·1984
Same author

Presence of human papillomavirus in verrucous carcinoma (Ackerman) of the vagina. Immunocytochemical, ultrastructural, and DNA hybridization studies.

Archives of pathology & laboratory medicine·1984
Same journal

"Highlights from JAAD International: Noninvasive imaging for basal cell carcinoma".

Journal of the American Academy of Dermatology·2026
Same journal

Effect of Primary Prophylaxis for Pneumocystis Pneumonia in Patients on Rituximab for Immune-Mediated Dermatologic Conditions: A Systematic Review and Meta-Analysis.

Journal of the American Academy of Dermatology·2026
Same journal

Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study.

Journal of the American Academy of Dermatology·2026
Same journal

Real-World Effectiveness and Safety of Ritlecitinib in Adolescents with Severe Alopecia Areata: A 36-Week Single-Center Study.

Journal of the American Academy of Dermatology·2026
Same journal

Liquid Biopsy in Cutaneous Oncology: Current Practice and Future Directions.

Journal of the American Academy of Dermatology·2026
Same journal

Ethically protecting immunosuppressed patients in shared dermatology spaces.

Journal of the American Academy of Dermatology·2026
See all related articles

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Traditional immunization methods involve inactivated or live, attenuated viruses.
  • Modern approaches focus on subunit vaccines derived from viral components.

Purpose of the Study:

  • To review modern methods for viral vaccine preparation, emphasizing subunit vaccines.
  • To highlight the application of recombinant DNA technology in vaccine development.

Main Methods:

  • Extraction and purification of immunogenic viral parts.
  • Synthesis of polypeptide immunogens.
  • Recombinant deoxyribonucleic acid (DNA) techniques for producing immunogenic viral portions.

Main Results:

  • Subunit vaccines can be produced without viral DNA, rendering them non-infectious and likely non-oncogenic.

Related Experiment Videos

  • A bovine papillomavirus vaccine using recombinant DNA is in clinical trials.
  • A herpes simplex virus vaccine using glycoprotein D has been developed and tested in animals.

    • Conclusions:

    • Recombinant DNA technology enables the creation of safer, subunit viral vaccines.
    • Ongoing research shows promise for vaccines against bovine papillomavirus and herpes simplex virus.